کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5555328 | 1559740 | 2017 | 8 صفحه PDF | دانلود رایگان |
- IL-10 attenuates inflammatory reaction in the primary VM neuron-enriched cultures.
- IL-10 attenuates neuronal apoptosis in the primary VM neuron-enriched cultures.
- IL-10 attenuates neuronal loss in the primary VM neuron-enriched cultures.
- IL-10 directly protects VM neurons through IL-10Rα-JAK-STAT3 pathway.
- IL-10 may be a good therapeutic agent against PD.
Neuroinflammation plays an important role in the pathogenesis of Parkinson's disease. Interleukin (IL)-10 is one of the most important and best anti-inflammatory cytokines. The objective of this report is to investigate whether IL-10 has any role in protecting ventral mesencephalic (VM) neurons in in vitro model of neuroinflammation. In this study, primary neuron-enriched culture was prepared from the VM tissues of E14 embryos of rats. The cells were pretreated with IL-10 (15 or 50Â ng/mL) for 1Â h followed by lipopolysaccharide (LPS, 50Â ng/mL) application. We found LPS induced neuronal apoptosis and loss while pretreatment with IL-10 reduced neuronal damage after exposure of LPS toxicity. Furthermore, signal transduction pathways related to IL-10 in VM neurons were studied in inflammatory condition. We used both shRNA and pharmacologic inhibition to determine the role of the IL-10 receptor (IL-10R) and its downstream signaling pathways in LPS-induced VM neuronal toxicity. Silence of the IL-10R gene in VM neurons abolished IL-10 mediated protection and the properties of anti-inflammatory and anti-apoptosis. IL-10 also induced phosphorylation of signal transducer and activator of transcription (STAT) 3 in VM neurons. Pretreatment with the specific Janus kinase (JAK) inhibitor reduced STAT3 phosphorylation and blocked IL-10 mediated protection against LPS. These findings suggest that IL-10 provides neuroprotection by acting via IL-10R and its down-stream JAK-STAT3 signal pathways in VM neurons.
Journal: International Immunopharmacology - Volume 50, September 2017, Pages 353-360